REPORT ID 6839

Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size, Status and Forecast 2022

Publish Date
1-Nov-17
Pages
96
Format
Electronic (PDF)

This report studies the global Therapies for Resistant and Recurrent Metastatic Cancer market, analyzes and researches the Therapies for Resistant and Recurrent Metastatic Cancer development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
    Miraca Holdings
    Proteome Sciences
    Boreal Genomics
    Oxford Gene Technology
    Illumina
    Neogenomics Laboratories
    Biotheranostics
    Nanostring Technologies
    Genomic Health
    Thermo Fisher Scientific

Market segment by Regions/Countries, this report covers
    United States
    EU
    Japan
    China
    India
    Southeast Asia

Market segment by Type, Therapies for Resistant and Recurrent Metastatic Cancer can be split into
    Breast Cancer
    Endocrine Cancer
    Leukemia
    Lymphoma
    Bladder
    Colorectal
    Kidney
    Ovary
    Pancreas
    Others

Market segment by Application, Therapies for Resistant and Recurrent Metastatic Cancer can be split into
    Chemotherapy
    Hormone Therapy
    Biotherapy
    Radiation Therapy
    Surgery
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.


 
			   
Table of Contents

Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size, Status and Forecast 2022
1 Industry Overview of Therapies for Resistant and Recurrent Metastatic Cancer
    1.1  Therapies for Resistant and Recurrent Metastatic Cancer Market Overview
        1.1.1 Therapies for Resistant and Recurrent Metastatic Cancer Product Scope
        1.1.2 Market Status and Outlook
    1.2 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Analysis by Regions
        1.2.1 United States
        1.2.2 EU
        1.2.3 Japan
        1.2.4 China
        1.2.5 India
        1.2.6 Southeast Asia
    1.3 Therapies for Resistant and Recurrent Metastatic Cancer Market by Type
        1.3.1 Breast Cancer
        1.3.2 Endocrine Cancer
        1.3.3 Leukemia
        1.3.4 Lymphoma
        1.3.5 Bladder
        1.3.6 Colorectal
        1.3.7 Kidney
        1.3.8 Ovary
        1.3.9 Pancreas
        1.3.10 Others
    1.4 Therapies for Resistant and Recurrent Metastatic Cancer Market by End Users/Application
        1.4.1 Chemotherapy
        1.4.2 Hormone Therapy
        1.4.3 Biotherapy
        1.4.4 Radiation Therapy
        1.4.5 Surgery
        1.4.6 Others

2 Global Therapies for Resistant and Recurrent Metastatic Cancer Competition Analysis by Players
    2.1 Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Value) by Players (2016 and 2017)
    2.2 Competitive Status and Trend
        2.2.1 Market Concentration Rate
        2.2.2 Product/Service Differences
        2.2.3 New Entrants
        2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
    3.1 Miraca Holdings
        3.1.1 Company Profile
        3.1.2 Main Business/Business Overview
        3.1.3 Products, Services and Solutions
        3.1.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
        3.1.5 Recent Developments
    3.2 Proteome Sciences
        3.2.1 Company Profile
        3.2.2 Main Business/Business Overview
        3.2.3 Products, Services and Solutions
        3.2.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
        3.2.5 Recent Developments
    3.3 Boreal Genomics
        3.3.1 Company Profile
        3.3.2 Main Business/Business Overview
        3.3.3 Products, Services and Solutions
        3.3.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
        3.3.5 Recent Developments
    3.4 Oxford Gene Technology
        3.4.1 Company Profile
        3.4.2 Main Business/Business Overview
        3.4.3 Products, Services and Solutions
        3.4.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
        3.4.5 Recent Developments
    3.5 Illumina
        3.5.1 Company Profile
        3.5.2 Main Business/Business Overview
        3.5.3 Products, Services and Solutions
        3.5.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
        3.5.5 Recent Developments
    3.6 Neogenomics Laboratories
        3.6.1 Company Profile
        3.6.2 Main Business/Business Overview
        3.6.3 Products, Services and Solutions
        3.6.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
        3.6.5 Recent Developments
    3.7 Biotheranostics
        3.7.1 Company Profile
        3.7.2 Main Business/Business Overview
        3.7.3 Products, Services and Solutions
        3.7.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
        3.7.5 Recent Developments
    3.8 Nanostring Technologies
        3.8.1 Company Profile
        3.8.2 Main Business/Business Overview
        3.8.3 Products, Services and Solutions
        3.8.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
        3.8.5 Recent Developments
    3.9 Genomic Health
        3.9.1 Company Profile
        3.9.2 Main Business/Business Overview
        3.9.3 Products, Services and Solutions
        3.9.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
        3.9.5 Recent Developments
    3.10 Thermo Fisher Scientific
        3.10.1 Company Profile
        3.10.2 Main Business/Business Overview
        3.10.3 Products, Services and Solutions
        3.10.4 Therapies for Resistant and Recurrent Metastatic Cancer Revenue (Value) (2012-2017)
        3.10.5 Recent Developments

4 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size by Type and Application (2012-2017)
    4.1 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size by Type (2012-2017)
    4.2 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size by Application (2012-2017)
    4.3 Potential Application of Therapies for Resistant and Recurrent Metastatic Cancer in Future
    4.4 Top Consumer/End Users of Therapies for Resistant and Recurrent Metastatic Cancer

5 United States Therapies for Resistant and Recurrent Metastatic Cancer Development Status and Outlook
    5.1 United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
    5.2 United States Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)

6 EU Therapies for Resistant and Recurrent Metastatic Cancer Development Status and Outlook
    6.1 EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
    6.2 EU Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)

7 Japan Therapies for Resistant and Recurrent Metastatic Cancer Development Status and Outlook
    7.1 Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
    7.2 Japan Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)

8 China Therapies for Resistant and Recurrent Metastatic Cancer Development Status and Outlook
    8.1 China Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
    8.2 China Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)

9 India Therapies for Resistant and Recurrent Metastatic Cancer Development Status and Outlook
    9.1 India Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
    9.2 India Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)

10 Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Development Status and Outlook
    10.1 Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size (2012-2017)
    10.2 Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Market Size and Market Share by Players (2016 and 2017)

11 Market Forecast by Regions, Type and Application (2017-2022)
    11.1 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Value) by Regions (2017-2022)
        11.1.1 United States Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
        11.1.2 EU Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
        11.1.3 Japan Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
        11.1.4 China Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
        11.1.5 India Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
        11.1.6 Southeast Asia Therapies for Resistant and Recurrent Metastatic Cancer Revenue and Growth Rate (2017-2022)
    11.2 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size (Value) by Type (2017-2022)
    11.3 Global Therapies for Resistant and Recurrent Metastatic Cancer Market Size by Application (2017-2022)

12 Therapies for Resistant and Recurrent Metastatic Cancer Market Dynamics
    12.1 Therapies for Resistant and Recurrent Metastatic Cancer Market Opportunities
    12.2 Therapies for Resistant and Recurrent Metastatic Cancer Challenge and Risk
        12.2.1 Competition from Opponents
        12.2.2 Downside Risks of Economy
    12.3 Therapies for Resistant and Recurrent Metastatic Cancer Market Constraints and Threat
        12.3.1 Threat from Substitute
        12.3.2 Government Policy
        12.3.3 Technology Risks
    12.4 Therapies for Resistant and Recurrent Metastatic Cancer Market Driving Force
        12.4.1 Growing Demand from Emerging Markets
        12.4.2 Potential Application

13 Market Effect Factors Analysis
    13.1 Technology Progress/Risk
        13.1.1 Substitutes
        13.1.2 Technology Progress in Related Industry
    13.2 Consumer Needs Trend/Customer Preference
    13.3 External Environmental Change
        13.3.1 Economic Fluctuations
        13.3.2 Other Risk Factors

14 Research Finding/Conclusion

15 Appendix
    Methodology
    Analyst Introduction
    Data Source